It is widely known that mammography is not sufficient to detect cancer in women with dense breasts, a risk factor that increases cancer incidence four to six times. While mammography remains the primary imaging modality for breast cancer screening, the need for a better imaging approach is critical to address this large underserved population.
Seventy percent of Asian women have dense breasts and studies show that mammography alone is not an adequate primary detection method for these women because dense breast tissue can mimic or hide cancer on a mammogram.
Hand-held ultrasound has the potential to identify more cancers but is cumbersome and inconsistent, resulting in frequent false positives. Early automated breast ultrasound systems are operator dependent and provide fragmented, sectional scanning, offering only b-mode imaging, a decades-old technology.
Delphinus Medical Technologies, Inc. has taken on the challenge to transform care for women with dense breasts around the world. SoftVue™ 3-D whole breast ultrasound is a breakthrough solution working to address the most difficult-to-detect dense breast patient population, bringing efficiencies to clinical workflow, while creating a superior imaging experience for women.
SoftVue incorporates the first-ever circular transducer, imaging the entire breast volume in one scan, moving from nipple to chest wall, using no compression or radiation. SoftVue’s TriAD™ technology gathers reflection echoes for tissue structure and captures signals transmitted through the breast for tissue characteristics. This unrivaled design and revolutionary imaging technique delivers unprecedented clarity in dense breast imaging, for a gentle, calming imaging experience appreciated by women.
Given the sizable global market, supported by breast density legislation in the United States, a growing worldwide awareness of cancer risk in dense tissue and mammography’s deficiencies, Delphinus is changing clinical thought and practice of early cancer detection for women with dense breasts.
